All data are based on the daily closing price as of December 20, 2024
v

Voronoi

310210.KQ
47.16 USD
-1.73
-3.54%

Overview

Last close
47.16 usd
Market cap
846.76M usd
52 week high
88.62 usd
52 week low
21.07 usd
Target price
110.76 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
24.3992
Price/Book Value
16.4528
Enterprise Value
805.24M usd
EV/Revenue
51.1462
EV/EBITDA
-15.8405

Key financials

Revenue TTM
407505.58 usd
Gross Profit TTM
6.76M usd
EBITDA TTM
-20.66M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
84.99B usd
Net debt
N/A usd

About

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was founded in 2015 and is based in Incheon, South Korea.
  • Symbol
    310210.KQ
  • Exchange
    KQ
  • Isin
    N/A
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Sunghwan Kim Ph.D.
  • Headquarter
    Incheon
  • Web site
    https://voronoi.io
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top